Business Description
Organogenesis Holdings Inc
NAICS : 325412
SIC : 2834
ISIN : US68621F1021
Share Class Description:
ORGO: Class ADescription
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced wound care, surgical and sports medicine markets. Its product category includes Advanced Wound Care and Surgical and Sports Medicine. It has single operating segment which has regenerative medicine. The company generates maximum revenue from Advanced Wound Care products. Some of its products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, Dermagraft and others.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.87 | |||||
| Equity-to-Asset | 0.61 | |||||
| Debt-to-Equity | 0.43 | |||||
| Debt-to-EBITDA | 3.31 | |||||
| Interest Coverage | 5.72 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 2.38 | |||||
| Beneish M-Score | -2.84 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 2.4 | |||||
| 3-Year EBITDA Growth Rate | -6.7 | |||||
| 3-Year EPS without NRI Growth Rate | -32.5 | |||||
| 3-Year Book Growth Rate | 24.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | 6.84 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 42.68 | |||||
| 9-Day RSI | 40.97 | |||||
| 14-Day RSI | 41.34 | |||||
| 6-1 Month Momentum % | 16.88 | |||||
| 12-1 Month Momentum % | 34.47 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.8 | |||||
| Quick Ratio | 2.44 | |||||
| Cash Ratio | 1.29 | |||||
| Days Inventory | 90.39 | |||||
| Days Sales Outstanding | 75.23 | |||||
| Days Payable | 101.15 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.9 | |||||
| Shareholder Yield % | 1.73 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 75.42 | |||||
| Operating Margin % | 2.89 | |||||
| Net Margin % | 1.14 | |||||
| FCF Margin % | 1.51 | |||||
| ROE % | 1.82 | |||||
| ROA % | 1.09 | |||||
| ROIC % | 1.99 | |||||
| ROC (Joel Greenblatt) % | 5.71 | |||||
| ROCE % | 3.34 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 69.17 | |||||
| PE Ratio without NRI | 69.17 | |||||
| PS Ratio | 0.76 | |||||
| PB Ratio | 1.17 | |||||
| Price-to-Tangible-Book | 1.4 | |||||
| Price-to-Free-Cash-Flow | 50.82 | |||||
| Price-to-Operating-Cash-Flow | 10.78 | |||||
| EV-to-EBIT | 27.47 | |||||
| EV-to-Forward-EBIT | 5.05 | |||||
| EV-to-EBITDA | 9.59 | |||||
| EV-to-Forward-EBITDA | 4.15 | |||||
| EV-to-Revenue | 0.8 | |||||
| EV-to-Forward-Revenue | 0.78 | |||||
| EV-to-FCF | 52.74 | |||||
| Price-to-Projected-FCF | 3.77 | |||||
| Price-to-Graham-Number | 2.08 | |||||
| Price-to-Net-Current-Asset-Value | 7.55 | |||||
| Earnings Yield (Greenblatt) % | 3.64 | |||||
| FCF Yield % | 1.99 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ORGO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Organogenesis Holdings Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 433.14 | ||
| EPS (TTM) ($) | 0.036 | ||
| Beta | 1.23 | ||
| Volatility % | 121.97 | ||
| 14-Day RSI | 41.34 | ||
| 14-Day ATR ($) | 0.213625 | ||
| 20-Day SMA ($) | 2.7375 | ||
| 12-1 Month Momentum % | 34.47 | ||
| 52-Week Range ($) | 1.96 - 4.705 | ||
| Shares Outstanding (Mil) | 132.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Organogenesis Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Organogenesis Holdings Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Organogenesis Holdings Inc Frequently Asked Questions
What is Organogenesis Holdings Inc(ORGO)'s stock price today?
The current price of ORGO is $2.49. The 52 week high of ORGO is $4.71 and 52 week low is $1.96.
When is next earnings date of Organogenesis Holdings Inc(ORGO)?
The next earnings date of Organogenesis Holdings Inc(ORGO) is 2024-05-09.
Does Organogenesis Holdings Inc(ORGO) pay dividends? If so, how much?
Organogenesis Holdings Inc(ORGO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers